Jacobs Bruce N. 4
4 · Kymera Therapeutics, Inc. · Filed Mar 3, 2025
Insider Transaction Report
Form 4
Jacobs Bruce N.
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-03-03$31.00/sh−1,281$39,717→ 201,886 total - Award
Stock Option (Right to Buy)
2025-03-03+60,000→ 60,000 totalExercise: $30.17Exp: 2035-03-02→ Common Stock (60,000 underlying) - Award
Common Stock
2025-03-03+30,000→ 208,921 total - Sale
Common Stock
2025-03-03$30.33/sh−5,754$174,502→ 203,167 total
Footnotes (5)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.
- [F2]Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.